Search clinical trials for: First Line

Total 22235 results

The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Korea, Republic of
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea

Ulcerative Colitis

Korea, Republic of
Peking Union Medical College Hospital

Recruiting

First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Gastrointestinal Neuroendocrine Carcinoma

China
Bristol-Myers Squibb

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
Chinese PLA General Hospital
The General Hospital of Western Theater Command; First Hospital of China Medical... and other collaborators

Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Ampullary Carcinoma
Sun Yat-sen University

Not yet recruiting

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer | High Grade Serous Adenocarcinoma of Ovary | High Grade Endometrioid Ovarian Cancer | Fallopian-tube Cancer

China
GlaxoSmithKline
iTeos Therapeutics

Recruiting

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Neoplasms, Head and Neck

United States, Italy, Spain, Taiwan, Germany, Greece, Korea, Republic of, Romania, Sweden, Turkey, Canada, Argentina, Finland, Brazil, Japan, Poland, Portugal, France, Denmark, Hungary, Norway
Centre Jean Perrin

Recruiting

Impact of Implementing the Modified A-DIVA Scale on Successful Access to a Venous Line on the First Attempt (DIVAPERF)

Chronic Disease

France
Changhai Hospital

Not yet recruiting

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression | Esophageal Squamous Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer (RCT-PAAG)

Pancreatic Adenocarcinoma Metastatic

China
First Affiliated Hospital of Zhejiang University

Not yet recruiting

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Palmoplantar Psoriasis | Genital Psoriasis

United States, Germany, Spain, Italy, Poland, Argentina, Canada
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, Denmark, United States, Spain, Australia, Japan, France, Korea, Republic of, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, United Kingdom, Czechia, Germany, Poland
Institut Paoli-Calmettes

Not yet recruiting

Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients (GemSign-01)

Cancer Of Pancreas
University of Cologne

Not yet recruiting

Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma (Pembro-FLASH)

Hodgkin Lymphoma

Germany
Nataliya Uboha
Gilead Sciences; University of Wisconsin, Madison; Arcus Biosciences, Inc.

Recruiting

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Carcinoma

United States
Bristol-Myers Squibb

Recruiting

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants (MAXILUS)

Myelodysplastic Syndromes

Spain, United States, France, Italy, Belgium, Germany, Poland, Czechia, Puerto Rico
Fudan University

Not yet recruiting

Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma

Advanced Mucosal Melanoma
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Solid Tumor

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Neuroendocrine Tumors

China
Bristol-Myers Squibb

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Relapsed or Refractory T-cell Lymphomas

Japan
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
InxMed (Shanghai) Co., Ltd.

Recruiting

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Small Cell Lung Cancer Extensive Stage

China
Peking Union Medical College Hospital
Henan Cancer Hospital; Shengjing Hospital; Sun Yat-Sen Memorial Hospital of Sun... and other collaborators

Recruiting

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 (TA56)

Gestational Trophoblastic Neoplasia

China
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms

Digestive System Neoplasms

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

China, United States, Taiwan, Japan, Korea, Republic of, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Peru, Poland, Portugal, Spain, Switzerla... and more
Peking Union Medical College Hospital
Henan Cancer Hospital; Shengjing Hospital; Sun Yat-Sen Memorial Hospital of Sun... and other collaborators

Not yet recruiting

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 7 (TA7)

Gestational Trophoblastic Neoplasia

China
Fudan University

Recruiting

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Non-small Cell Lung Cancer | Brain Metastases

China
Samsung Medical Center

Not yet recruiting

An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma

Prostatic Adenocarcinoma

Korea, Republic of
Sun Yat-sen University

Recruiting

Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors

Pituitary Adenoma | Neuroendocrine Tumors

China
Bristol-Myers Squibb

Recruiting

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

Lupus

United States, Argentina, Germany, Mexico, Poland, Romania, Bulgaria, Spain
Eastern Hepatobiliary Surgery Hospital

Recruiting

Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC

Gallbladder Cancer

China
Fudan University

Recruiting

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Colorectal Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

China, Taiwan, United States, Australia, Japan, Korea, Republic of, United Kingdom, Canada, Israel, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
Qian Chu
Akeso Pharmaceuticals, Inc.

Recruiting

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative (ACHELOUS)

Carcinoma, Non-Small-Cell Lung

China
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
Akeso

Not yet recruiting

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Centre Georges Francois Leclerc

Recruiting

Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy (FOLFIRINOX3 P)

Metastatic Pancreatic Cancer

France
IDEAYA Biosciences

Recruiting

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Metastatic Uveal Melanoma

United States, Canada, Israel, Spain, Australia, Germany, France, Italy, United Kingdom, Netherlands, Belgium, Poland, Switzerland
Bristol-Myers Squibb

Not yet recruiting

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

Healthy Participants

United States
BeiGene

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

United States, New Zealand, Australia, China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Gastric Cancer

China
Zhongshan People's Hospital, Guangdong, China

Recruiting

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Nasopharyngeal Carcinoma

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants

Healthy Male Volunteers

United States

Search clinical trials for: First Line

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations